[Clinical study on cefteram pivoxil in pediatric field]. 1989

M Fujita, and T Kanda, and E Nagayama
Department of Pediatrics, Kanto Teishin Hospital.

Cefteram pivoxil (CFTM-PI, T-2588) was administered to pediatric patients with acute infectious diseases, and a summary of the results obtained are as follows. 1. Pharmacokinetic parameters determined in 1 patient appears to be comparable to those of adults. 2. Clinical efficacy was studied on 16 children with acute urinary tract infections, acute upper respiratory infections, acute sinusitis, acute otitis media and acute cervical lymphadenitis. Responses to the treatment were excellent in 7 (43.8%) and good in 9 (56.3%). 3. No adverse reactions were noted in this study.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D015281 Cefmenoxime A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. Abbott-50192,Cefmax,Cefmenoxime Hydrochloride,Cefmenoxime Hydrochloride (2:1),SCE-1365,Abbott 50192,Abbott50192,Hydrochloride, Cefmenoxime,SCE 1365,SCE1365

Related Publications

M Fujita, and T Kanda, and E Nagayama
August 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
August 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
September 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
August 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
September 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
September 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
September 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
August 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
August 1989, The Japanese journal of antibiotics,
M Fujita, and T Kanda, and E Nagayama
May 1991, The Japanese journal of antibiotics,
Copied contents to your clipboard!